Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | SHBG | P04278 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979738 | 0.84 | TDP1 (0.40) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4978357 | 0.84 | NR3C1 (0.61) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4978346 | 0.84 | NR3C1 (0.61) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4983294 | 0.83 | TDP1 (0.37) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818843 | 0.81 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818856 | 0.81 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4982043 | 0.79 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4255031 | 0.79 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4822515 | 0.79 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4981552 | 0.79 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | claimed |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | claimed |
| EP-1505072-A2 | Eplerenone crystalline form exhiniting enhanced dissolution rate | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | claimed |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION | 2002-03-28 | — | — | US | claimed |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | BARTON KATHLEEN P | 2009-06-11 | — | — | US | disclosed |
| EP-1289507-B1 | USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS | PHARMACIA CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S | 2008-01-31 | — | — | US | disclosed |
| EP-1148061-B1 | Epoxidation process | SEARLE LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070191324-A1 | Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | WILLIAMS GORDON H | 2007-08-16 | — | — | US | disclosed |
| EP-1303305-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7112669-B2 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1303308-B1 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | PHARMACIA CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | disclosed |
| EP-0944644-B1 | PROCESSES FOR PREPARATION OF 3-KETO-7alpha-ALKOXYCARBONYL-delta-4,5- STEROIDS AND INTERMEDIATES USEFUL THEREIN | SEARLE & CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2002-09-05 | — | — | US | disclosed |
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | PHARMACIA CORPORATION | 2002-08-15 | — | — | US | disclosed |
| EP-1223174-A2 | Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION | 2002-03-28 | — | — | US | disclosed |
| EP-1148061-A2 | Process for preparation of 9, 11- epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | NR3C2, MC2R, AGTR1 | NR3C1 8/4885TDP1 2608/4885MEN1 3115/4885 |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 19/4885TDP1 4507/4885MEN1 1755/4885 |
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885TDP1 4447/4885MEN1 1812/4885 |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885TDP1 4447/4885MEN1 1812/4885 |
| US-20070191324-A1 | Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist | NR3C2, CYP21A2, REN | NR3C1 20/4885TDP1 4077/4885MEN1 1291/4885 |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB2, ADRB1, NR3C2 | NR3C1 31/4885TDP1 4865/4885MEN1 2795/4885 |
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | NR3C1 89/4885TDP1 4310/4885MEN1 1070/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | NR3C1 68/4885TDP1 4583/4885MEN1 1738/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | NR3C1 88/4885TDP1 4882/4885MEN1 1977/4885 |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885TDP1 4324/4885MEN1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.